Have a feature idea you'd love to see implemented?
Let us know!
LEGN Legend Biotech Corp
Price (delayed)
$43.97
Market cap
$8.02B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.54
Enterprise value
$7.1B
legend biotech corporation is an emerging company focusing on the development of the best-in-class immunotherapy technology for cancer cure. teamed up with outstanding immunologists and molecular biologists, legend has generated
Highlights
The revenue has surged by 177% year-on-year and by 33% since the previous quarter
The gross margin has soared by 107% YoY and by 15% from the previous quarter
The quick ratio has contracted by 42% YoY and by 15% from the previous quarter
The equity is down by 18% YoY
Key stats
What are the main financial stats of LEGN
Market
Valuations
Earnings
Shares outstanding
182.28M
Market cap
$8.02B
Enterprise value
$7.1B
Price to earnings (P/E)
N/A
Price to book (P/B)
6.92
Price to sales (P/S)
17.58
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
15.58
Revenue
$455.99M
EBIT
-$264.61M
EBITDA
-$243M
Free cash flow
-$210.73M
Per share
Balance sheet
Liquidity
EPS
-$1.54
Free cash flow per share
-$1.16
Book value per share
$6.36
Revenue per share
$2.5
TBVPS
$9.85
Total assets
$1.8B
Total liabilities
$639.18M
Debt
$338.93M
Equity
$1.16B
Working capital
$1.13B
Debt to equity
0.29
Current ratio
4.84
Quick ratio
4.44
Net debt/EBITDA
3.75
Margins
Efficiency
Dividend
EBITDA margin
-53.3%
Gross margin
60.3%
Net margin
-62.5%
Operating margin
-53.3%
Return on assets
-15.7%
Return on equity
-23.2%
Return on invested capital
-39.4%
Return on capital employed
-17.6%
Return on sales
-58%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
LEGN stock price
How has the Legend Biotech stock price performed over time
Intraday
-2.36%
1 week
-0.11%
1 month
-4.25%
1 year
-32.76%
YTD
-26.92%
QTD
-9.77%
Financial performance
How have Legend Biotech's revenue and profit performed over time
Revenue
$455.99M
Gross profit
$274.87M
Operating income
-$243.24M
Net income
-$285.01M
Gross margin
60.3%
Net margin
-62.5%
The revenue has surged by 177% year-on-year and by 33% since the previous quarter
The gross margin has soared by 107% YoY and by 15% from the previous quarter
The operating margin has soared by 81% YoY and by 43% QoQ
Legend Biotech's net margin has surged by 81% YoY and by 54% QoQ
Growth
What is Legend Biotech's growth rate over time
Valuation
What is Legend Biotech stock price valuation
P/E
N/A
P/B
6.92
P/S
17.58
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
15.58
The EPS has surged by 51% year-on-year and by 40% since the previous quarter
The stock's price to book (P/B) is 45% less than its 5-year quarterly average of 12.8 and 16% less than its last 4 quarters average of 8.4
The equity is down by 18% YoY
The revenue has surged by 177% year-on-year and by 33% since the previous quarter
The P/S is 71% less than the 5-year quarterly average of 62.9 and 47% less than the last 4 quarters average of 34.2
Efficiency
How efficient is Legend Biotech business performance
The return on sales has surged by 81% year-on-year and by 55% since the previous quarter
LEGN's return on invested capital has surged by 66% year-on-year and by 38% since the previous quarter
The company's return on equity has surged by 57% YoY and by 36% QoQ
LEGN's return on assets has surged by 56% year-on-year and by 38% since the previous quarter
Dividends
What is LEGN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for LEGN.
Financial health
How did Legend Biotech financials performed over time
Legend Biotech's total assets is 181% more than its total liabilities
The quick ratio has contracted by 42% YoY and by 15% from the previous quarter
Legend Biotech's current ratio has decreased by 40% YoY and by 14% QoQ
Legend Biotech's debt is 71% lower than its equity
The debt to equity has grown by 26% YoY
The equity is down by 18% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.